A clot-dissolving tissue plasminogen activator (tPA), tenecteplase is now indicated ... Tenecteplase thus officially joins the other stroke thrombolytic approved stateside, alteplase (Activase ...

Additionally, a very low dose of tPA is infused in combination with ... a novel and highly differentiated ultrasound facilitated, thrombolytic enhanced thrombectomy system for venous and arterial ...

DiaMedica Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke and preeclampsia, today provided a business update and ...

Participants treated with tissue plasminogen activator (tPA) or tenecteplase (TNK), (thrombolytic agents) intended to dissolve blood clots, are eligible for participation if they continue to ...

SonoVascular, Inc., a clinical stage medical device company focused on bringing to market its SonoThrombectomy™ System for venous thromboembolism (VTE), a novel treatment solution intended to provide ...

Operator: Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Full Year 2024 Conference Call.

And for patients who haven’t improved for at least six hours after thrombolytic treatment ... particularly with regard to the TPA non-responders, are you starting to see an improvement in ...

For example, it has been 13 years since the introduction of thrombolysis into the standard ... thrombolytics are streptokinase and accelerated tPA administration. However, only about 50% of ...